Maximum standardized uptake value on 18F-Fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas

Pancreas

Volumn 43, Issue 7, 2014, Pages 1060-1065

  Kitasato, Yuhei ^a   Yasunaga, Masafumi ^a   Okuda, Koji ^a   Kinoshita, Hisafumi ^a   Tanaka, Hiroyuki ^a   Okabe, Yoshinobu ^a   Kawahara, Akihiko ^a   Kage, Masayoshi ^a   Kaida, Hayato ^a   Ishibashi, Masatoshi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

18F fluoro 2 deoxy glucose positron emission tomography computed tomography; Epidermal growth factor receptor; Glucose transporter 1; Glucose transporter 3; Invasive ductal carcinoma of the pancreas; Maximum standardized uptake value

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; RADIOPHARMACEUTICAL AGENT; TUMOR PROTEIN;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CHEMISTRY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIMODAL IMAGING; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; RETROSPECTIVE STUDY; SCINTISCANNING; SINGLE BLIND PROCEDURE; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM PROTEINS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84914174192     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000185     Document Type: Article

References (30)

1. Egawa S, Toma H, Ohigashi H, et al. Japan pancreatic cancer registry; 30th year anniversary. Pancreas. 2012;41:985-992.
2. Audrey V, Joseph H, Rich S, et al. Pancreatic cancer. Lancet. 2011; 378:607-620.
3. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223:273-279.
4. Robert JC, Ayesha SB, Buddhiwardhan O, et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151-159.
5. Suzuki H, Hasegawa Y, Terada A, et al. FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma. Oral Oncol. 2009;45:569-573.
6. Kaira K, Serizawa M, Koh Y, et al. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Nucl Med. 2012;48:1244-1254.
7. Park SG, Lee JH, Lee WA, et al. Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma. Nucl Med Biol. 2012;39:1167-1172.
8. Cem P, Erkan T, Cem O, et al. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiat Oncol. 2012;7:37.
9. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase 18F-FDG-PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
10. Baardwijk AV, Dooms C, Suylen RJ, et al. The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43:1392-1398.
11. Kaira K, Endo M, Abe M, et al. Biologic correlation of 2-18F-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28: 3746-3753.
12. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1988;39:1727-1735.
13. Basturk O, Singh R, Kaygusuz E, et al. GLUT-1 expression in pancreatic neoplasia. Pancreas. 2011;40:187-192.
14. Sun HC, Qiu ZJ, Liu J, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol. 2007;30:1359-1367.
15. Uegaki K, Nio Y, Inoue S, et al. Clinicopathological significance of epidermal growth factor and receptor in human pancreatic cancer. Anticancer Res. 1997;17:3841-3847.
16. Dong M, Nio Y, Guo KJ, et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 1998;18:4613-4619.
17. Gong Y, Zhang L, He T, et al. Pancreaticoduodenectomy combined with vascular resection and reconstruction for patients with locally advanced pancreatic cancer: a multicenter, retrospective analysis. PLoS One. 2013;8:e70340.
18. Mullar SA, Hartel M, Mehrabi A, et al. Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg. 2009;13:784-792.
19. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035-1046.
20. Papalezova KT, Tyler DS, Blazer DG, et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 2012;106:111-118.
21. Okamoto K, Koyama I, Miyazawa M, et al. Preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol. 2011;16:39-44.
22. Ito H, Duxbury M, Zinner MJ, et al. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery. 2004;136:548-556.
23. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter GLUT-1 in human cancers. Cancer Res. 1996;56:1164-1167.
24. Friess H, Wang L, Zhu Z, et al. Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Ann Surg. 1999;230:767-774.
25. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
26. Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 2004;29:e1-e9.
27. Valsecchi ME, McDonald M, Brody JB, et al. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118:3484-3493.
28. Gansauge F, Gansauge S, Schmidt E, et al. Prognostic significance of molecular alternations in human pancreatic carcinoma: an immunological study. Langenbecks Arch Surg. 1988;383:152-155.
29. Kuniyasu H, Ellis LM, Evans DB, et al. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res. 1999;5:25-33.
30. Mak RH, Digumarthy SR, Muzikansky A, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist. 2011;16:319-326.